Adentri (oral)

Biogen, Inc.

Drug Names(s): Tonapofylline, BG9928, CVT-124, BG9719, A1 Adenosine Receptor Antagonist

Description: BioMedTracker has separate drug profiles for the oral and intravenous formulations of Adentri. Please also see Adentri (intravenous).

ADENTRI (oral) is an A1 adenosine receptor antagonist.

Deal Structure: Biogen
In March 1997, Biogen licensed rights to develop adenosine A1 receptor inhibitors from CV Therapeutics. CV Therapeutics' original compound was known as CVT-124 (BG9719).

Astellas
In January 2009, Astellas Pharma announced that it submitted a proposal to the Board of Directors of CV Therapeutics to acquire all outstanding common shares of CV Therapeutics for $16.00 per share in cash.

Gilead
In March 2009, Gilead Sciences and CV Therapeutics announced the signing of a definitive agreement pursuant to which Gilead will acquire CV Therapeutics for $20.00 per share in cash through a tender offer and second step merger. The acquisition was completed in April 2009.

Partners: Gilead Sciences, Inc.

Adentri (oral) News

Pink Sheet Novartis’ Attention To Tropical Diseases Pays Off: Liver Fluke Drug Egaten Earns Priority Review Voucher

Scrip VIDEO: Start-up AFYX Applies Ultra-Sticky Patch Technology To Underserved Oral Mucosal Disease

Scrip Novo Nordisk Using Priority Review Voucher To Propel Oral Semaglutide To Market

Scrip Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy

Additional information available to subscribers only:

Targets
Routes
Catalysts
Designations
Events

Request a Free Demo Subscriber Login Search for another drug